Diet and Lifestyle for Gallbladder Disease on Mounjaro (tirzepatide for T2D): What Actually Works

How common is gallbladder disease on Mounjaro?

In the Mounjaro placebo-controlled trials in adults, acute gallbladder disease (cholelithiasis, biliary colic and cholecystectomy) was reported by 0.6% of tirzepatide-treated patients and 0% of placebo patients [1]. The label lists acute gallbladder disease as a warning and says that if cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated [1].

Pooled data are mixed. A meta-analysis of nine randomized trials with 9,871 participants found the composite of gallbladder or biliary disease more frequent with tirzepatide than with placebo or basal insulin (RR 1.97, 95% CI 1.14 to 3.42); cholelithiasis, cholecystitis and biliary disease were not each significant alone [2]. A meta-analysis of 13 trials in adults with obesity but without diabetes reported a more than 2.6-fold increase in gallbladder-related disorders with semaglutide but no significant biliary risk with tirzepatide [4].

What may raise the risk

Tirzepatide delays gastric emptying [1]. A review of GLP-1-based therapies says these treatments may increase the risk of biliary disease [5]. In the general epidemiology of cholesterol gallstones, the modifiable risk factors are obesity, rapid weight loss and a sedentary lifestyle [3].

Mounjaro is labeled for glycemic control in type 2 diabetes, in adults and children 10 and older, and for cardiovascular risk reduction in adults with type 2 diabetes at high risk; it is not labeled for weight loss [1]. Weight still falls: in the 40-week SURPASS-2 trial of adults with type 2 diabetes, weight reductions were greater with tirzepatide than with semaglutide [6].

Diet and activity

The label's diet and activity wording is general: Mounjaro is an adjunct to diet and exercise [1]. Appetite drops on the drug, which can make regular meals harder. Decreased appetite was reported by 5% on 5 mg, 10% on 10 mg and 11% on 15 mg versus 1% on placebo, and nausea, diarrhea, vomiting and constipation were all more frequent than on placebo [1]. Most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1]. A review of gallbladder disease lists fasting among the risk factors for biliary sludge [3].

Related label warnings

Two neighboring label warnings involve abdominal pain and fluid loss. The label describes persistent or severe abdominal pain, sometimes radiating to the back, as a possible sign of pancreatitis and says to discontinue Mounjaro if pancreatitis is suspected [1]. It also warns of acute kidney injury from volume depletion after nausea, vomiting or diarrhea and says to monitor renal function in patients reporting such reactions [1].